RedHill Biopharma Reports First Quarter 2021 Financial Results and Operational Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices edge lower on easing fears over Saudi supply disruption
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
RedHill Biopharma (RDHL) Tops Q1 EPS by 29c, Revenues Miss
May 27, 2021 7:03 AM EDTRedHill Biopharma (NASDAQ: RDHL) reported Q1 EPS of ($0.05), $0.29 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $20.6 million versus the consensus estimate of $22.7 million.
Dror Ben-Asher, RedHill's Chief Executive Officer, said: "The progress of our two novel, oral COVID-19 programs has put RedHill at the forefront of oral COVID-19... More
